1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > IMS Pharmaceutical Pricing & Reimbursement Concise Guide: UK

The Pharmaceutical Pricing & Reimbursement Concise Guides are established as the definitive reference and training text for P&R professionals around the world, drawing on the long-standing expertise of the IMS pricing and reimbursement specialists to provide industry players and decision makers with a thorough understanding of the rules and regulations governing P&R in international markets. This report covers key developments in P&R, market access, cost containment, trade margins and healthcare issues.

Table Of Contents

IMS Pharmaceutical Pricing and Reimbursement Concise Guide: UK
UK ...1
HEALTHCARE SYSTEM..1
Facts and Figures ..1
Market Indicators2
Provision and Funding ...4
Separate Administration ..5
England5
Scotland, Wales and Northern Ireland 7
PRICING...7
Prescription Drugs..7
2014 PPRS..8
Statutory Drug Price Controls10
Rebates and Discounts .10
Generic Drugs ..11
Branded .11
Unbranded.11
Reimbursement Prices ..11
Hospital Drugs..11
Procurement ..11
Average Selling Prices ..11
OTC Drugs ...12
REIMBURSEMENT 12
Admission to Reimbursement ..12
England..12
Scotland.15
Wales.16
Northern Ireland.17
Patient Access Schemes...17
Early Access to Medicines.19
Negative List and Grey List ...19
Reimbursement Categories .20
Reimbursement Prices.20
Drug Tariff..20
Hospital Reimbursement..22
Formularies22
Funding..22
Changes in Reimbursement Status .23
England..23
Scotland.25
Wales.25
Northern Ireland.25
Changes in Reimbursement Prices .26
Price Increases..26
Price Modulation27
Flexible Pricing ..27
Overspending 28
Patient Access Schemes...28
Generics 28
Health Service Medicines Regulations ..29
Other DH Proposals ..30
PHARMACOECONOMICS.30
Pharmacoeconomic Requirements..30
England..31
Scotland.36
Wales.37
Northern Ireland.38
Proposed Reforms.38
PRICE BUILD UP ...39
Wholesalers .39
Margins ..39
Background39
Retail Pharmacies 40
Margins ..40
Dispensing Fees41
Pharmacy Clawback..41
Background42
Drug Classification.42
Dispensing Doctors ..43
Sales Tax .43
COST CONTAINMENT ..43
Industry Paybacks43
PPRS.43
Health Service Medicines Regulations ..44
Promotional Costs44
Promotional Expenditure ...44
Code of Conduct45
Advertising.45
Patient Co-payments45
Healthcare .45
Pharmaceuticals 46
Prescribing Controls.46
Prescribing Budgets ..46
Prescribing Incentive Schemes .46
Prescribing Restrictions.47
Frameworks ...47
Local Formularies ..47
Prescribing Guidelines...47
Prescribing Data and Monitoring ...48
E-prescribing..49
Prescribing Powers49
Generics...50
Rx-to-OTC Switches 50
Switching Process .50
Parallel Trade...51
FUTURE DEVELOPMENTS ..52
Outlook.52
EU Referendum.52
Impact of EU Withdrawal on the Pharmaceutical Sector ..52
NHS Funding .54
Reform of NICE Appraisal Process ...55
Statutory Drug Price Controls57
Maximum Prices 57
Price Disclosure.58
Pharmacy Funding 58
Accelerated Access Review ..59
NAMES and ADDRESSES 60

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Major Depressive Disorder - Global Drug Forecast and Market Assessment to 2025

PharmaPoint: Major Depressive Disorder - Global Drug Forecast and Market Assessment to 2025

  • $ 10995
  • Industry report
  • October 2016
  • by Global Data

PharmaPoint: Major Depressive Disorder - Global Drug Forecast and Market Assessment to 2025 Summary Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. It is characterized ...

Colorectal Cancer KOL Insight 2016

Colorectal Cancer KOL Insight 2016

  • $ 8085
  • Industry report
  • October 2016
  • by Firstword Pharma

KOLs embrace novel MoAs as low survival rates drive search for new treatments Faced with persistently low survival rates, KOLs are calling for new approaches to treat late-stage colorectal cancer (CRC). ...

Frontier Pharma: Hepatitis C - Diverse Range of First-in-Class Host-Targeting and Direct-Acting Antivirals Offer Potential in Difficult-to-Treat Populations

Frontier Pharma: Hepatitis C - Diverse Range of First-in-Class Host-Targeting and Direct-Acting Antivirals Offer Potential in Difficult-to-Treat Populations

  • $ 6995
  • Industry report
  • December 2016
  • by GBI Research

Frontier Pharma: Hepatitis C - Diverse Range of First-in-Class Host-Targeting and Direct-Acting Antivirals Offer Potential in Difficult-to-Treat Populations Summary Hepatitis C is a blood-borne viral infection ...


Download Unlimited Documents from Trusted Public Sources

Therapy Market in the Netherlands

  • January 2017
    5 pages
  • Therapy  

  • Netherlands  

View report >

Global Therapy Market

  • January 2017
    32 pages
  • Therapy  

    Targeted Therap...  

    Monoclonal Anti...  

  • World  

View report >

Anti-Infective Market in India

  • January 2017
    4 pages
  • Anti-Infective  

    Blood Disease  

  • India  

    United States  

View report >

Therapy Market

1 day ago

Related Market Segments :

Therapy

ref:plp2016

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.